CSIMarket
 
Medpace Holdings Inc   (MEDP)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 
Price: $396.7600 $-7.85 -1.940%
Day's High: $406.47 Week Perf: -1.63 %
Day's Low: $ 395.27 30 Day Perf: 1.79 %
Volume (M): 427 52 Wk High: $ 419.42
Volume (M$): $ 169,536 52 Wk Avg: $262.61
Open: $404.18 52 Wk Low: $175.06



 Market Capitalization (Millions $) 12,636
 Shares Outstanding (Millions) 32
 Employees 3,900
 Revenues (TTM) (Millions $) 1,886
 Net Income (TTM) (Millions $) 283
 Cash Flow (TTM) (Millions $) 217
 Capital Exp. (TTM) (Millions $) 37

Medpace Holdings Inc
Medpace Holdings Inc. is a global contract research organization (CRO) that provides full-service clinical development solutions to its clients in the biopharmaceutical and medical device industries. Headquartered in Cincinnati, Ohio, the company was founded in 1992 by Dr. August Troendle, who still serves as its Chief Executive Officer.

Medpace offers a comprehensive range of clinical research services, including study design, protocol development, site identification and management, data management, biostatistics, regulatory affairs, clinical monitoring, medical writing, pharmacovigilance, and medical affairs. The company has specialized expertise in areas such as oncology, cardiology, neuroscience, infectious diseases, and rare diseases.

The company operates in over 45 countries and has a workforce of over 4,000 employees, including more than 1,200 medical personnel. Medpace has a proven track record of delivering high-quality clinical trials on time and within budget. As a result, it has established long-term partnerships with over 500 clients, ranging from small biotech startups to large pharmaceutical companies.

Medpace's quality management system is based on the principles of ICH Good Clinical Practice (GCP) and ISO 9001:2015. The company has been audited and inspected by regulatory authorities around the world, including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Medpace went public in 2016, raising $172.5 million in its initial public offering (IPO) on the NASDAQ stock exchange. Since then, the company's stock has steadily grown, reflecting the company's strong financial performance and growth prospects.

In summary, Medpace Holdings Inc. is a leading global CRO that provides full-service clinical development solutions to its clients in the biopharmaceutical and medical device industries. With a proven track record, specialized expertise, and a commitment to quality, Medpace is well-positioned to meet the increasing demand for clinical trial services in the healthcare industry.


   Company Address: 5375 Medpace Way Cincinnati 45227 OH
   Company Phone Number: 579-9911   Stock Exchange / Ticker: NASDAQ MEDP
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Medpace Holdings Inc

Medpace Holdings Inc Reports Impressive 13.12% Growth in Income for October to December 31, 2023 Financial Period

The stock market is often unpredictable, with ups and downs that can leave investors feeling uncertain. However, there are moments when a company's performance stands out, shining a light on the potential for fruitful investments. Medpace Holdings Inc, a Medical Laboratories company, is one such example, as their recent financial results have surpassed expectations.
In the October to December 31, 2023 financial time-frame, Medpace Holdings Inc's earnings per share (EPS) grew by an impressive 13.12% to $2.50 per share, compared to $2.21 from the previous year. Not only that, but the EPS also grew by 12.39% from $2.22 per share in the preceding quarter. These numbers indicate a consistent upward trend, demonstrating the company's ability to generate greater profits for its shareholders.

Medpace Holdings Inc

Medpace Holdings Inc. Records Impressive 8.29% Surge in Bottom-line Profits, Smashing Expectations for Q3 2023 Earnings Season

Bearish Outlook for Medpace Holdings Inc. in the Third Quarter of 2023 Earnings Season
Despite the positive earnings report for the third quarter of 2023, Medpace Holdings Inc may face challenges and decreasing profitability in the near future. While the company experienced a surge in income per share and revenue growth, there are several warning signs that investors should consider.
Firstly, while the income per share increased by 8.29% compared to last year, it is important to note that this growth rate is lower than in previous reporting seasons. In addition, the EPS surged by 15.03% from the previous reporting season, which is not a sustainable trend and may indicate a potential slowdown in future growth.

Medpace Holdings Inc

Medpace Holdings Inc Announces Skyrocketing Earnings in Q2 2023, with Revenue and Profits Surging by Over 30%

Medpace Holdings Inc Delivers Astonishing Q2 Earnings, Poses Promising Future for Investors
In a surprising turn of events, medical laboratories company, Medpace Holdings Inc, has reported astonishing earnings in the second quarter of 2023. The company's revenue saw an impressive increase of 31.224% to reach $460.87 million, while profit per share rose by 32.19% to $1.93 per share, year on year. These figures outperformed the revenue of $434.07 million and $2.27 per share reported in the preceding reporting season.
Furthermore, the bottom-line of $61.068 million for the financial period ending on June 30, 2023, experienced a remarkable growth of 23.72% from the net earnings of $49.360 million recorded in the same period a year ago. This robust performance signifies Medpace Holdings Inc's ability to thrive in an evolving market.






 

Medpace Holdings Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Medpace Holdings Inc does not provide revenue guidance.

Earnings Outlook
Medpace Holdings Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com